Trevor M. Polischuck, Ph.D. Public Equity Partner, OrbiMed Advisors LLC, updates on the Worldwide Healthcare Trust PLC.
Illumina was the top contributor, rising due to better than expected fourth quarter earnings and 2014 guidance. Medivation’s marketed prostate cancer drug, Xtandi (enzalutamide), were released in the month, pushing the stock up 25%.
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.
To request emailed copies of monthly fact sheets and other relevant information, please register below.